Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC)

Advances in Experimental Medicine and Biology

Volumn 431, Issue , 1998, Pages 657-660

  Kroep, J R ^a   Van Moorsei, C J A ^a   Veerman, G ^a   Voorn, D A ^a   Schultz, R M ^b   Worzalla, J F ^b   Tanzer, L R ^b   Merriman, R L ^c   Pinedo, H M ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ELI LILLY AND COMPANY   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCYTIDINE KINASE; DEOXYCYTIDINE PHOSPHATE DEAMINASE; GEMCITABINE; ISOENZYME; THYMIDINE KINASE; THYMIDINE KINASE 2; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALIA;

EID: 0031862454     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5381-6_127     Document Type: Conference Paper

References (10)

1. Ruiz van Haperen VWT, Peters GJ: New targets for pyrimidine antimetabolites in the treatment of solid tumors. 2. Deoxycytidine kinase. Pharmacy World & Science (1994) 16:104-112.
2. van Moorsel CJA, Peters GJ, Pinedo HM: gemcitabine: future prospects of single-agent and combination studies. The Oncologist (1997) 2:127-134.
3. Arner ESJ, Eriksson S: Mammalian deoxyribonucleoside kinases. Pharmac Ther ( 1995) 67:155-186.
4. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S: Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem (1991) 266:9032-9038.
5. HoDHW: Distribution of kinase and deaminase of 1-β-D-arabinofuranosylcytosine in tissues of man and mouse. Cancer Res (1973) 33:2816-2820.
6. Ruiz van Haperen VWT, Veerman G, Braakhuis BJM, Vermorken JB, Boven E, Leyva A, Peters GJ: Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts. Eur J Cancer (1993) 29A:2132-2137.
7. Ruiz van Haperen VWT, Veerman G, Vermorken JB, Pinedo HM, Peters GJ: Regulation of deoxycytidine and 2′,2′-difluorodeoxycytidine ( gemcitabine); effects of cytidine 5′-triphosphate and uridine 5′-triphosphate in relation to chemosensitivity for 2′,2′-difluorodeoxycytidine. Biochem Pharmacol (1996) 51:911-918.
8. Merriman RL, Hertel LW, Schultz RM, Houghton, PJ, Houghton JA, Rutherford PG, Tanzer LR, Boder GB, Grindey GB: Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs (1996)14:243-247.
9. Peters GJ, Laurensse EJ, Leyva A, Pinedo HM: Tissue homogenisation using a micro-dismembrator for the measurement of enzyme activities. Clin Chim Acta (1986)158:193-198.
10. Spasokoukotskaja T, Arner ESJ, Brosjo O, Gunven P, Juliusson G, Liliemark J and Eriksson S: Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxy-adenosine in human normal and tumor cells and tissues. Eur J Cancer (1995) 31A:202-8.